SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart

Summary: The authors hypothesized that despite similar cardiovascular event rates, the improved cardiovascular survival from sodium glucose transporter 2 (SGLT2) inhibition, seen clinically, could be via a direct cytoprotective effect, including protection against myocardial ischemia/reperfusion inj...

Full description

Bibliographic Details
Main Authors: Ven G. Lim, MBChB, Robert M. Bell, PhD, Sapna Arjun, PhD, Maria Kolatsi-Joannou, PhD, David A. Long, PhD, Derek M. Yellon, PhD, DSc
Format: Article
Language:English
Published: Elsevier 2019-02-01
Series:JACC: Basic to Translational Science
Online Access:http://www.sciencedirect.com/science/article/pii/S2452302X18302699

Similar Items